Amplia Therapeutics Halts Recruitment in AMPLICITY Trial
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Amplia Therapeutics Ltd. has announced the halt of recruitment in the AMPLICITY trial due to three observed dose-limiting toxicities related to the chemotherapy regimen mFOLFIRINOX, although no toxicity concerns were identified with narmafotinib, the company's lead drug. Patients already enrolled in the trial will continue their treatment while the company shifts focus to exploring less toxic chemotherapy combinations. The CEO expressed disappointment over the DLTs but emphasized the need to adapt to the evolving landscape of pancreatic cancer treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
- Amplia Reports Improved Responses & Survival in ACCENT trial
- Trading Halt
- Pause in Trading
- Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
Later from Amplia Therapeutics
- Accent Trial Mature Data Presented at International Conference
- Amplia and ANZGOG announce Ovarian Cancer Study
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
- Amplia Launches First Stage of Pivotal Narmafotinib Trial
- Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics